Wu R, Sun J, Xiao J, Liu Y, Xue F, Wang H, Tang L, Zhao Y, Li K, Yang R, Hu Y, Luke K-H, Poon M-C, Blanchette V S, Usuba K, Young N L
Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Haemophilia. 2017 May;23(3):430-436. doi: 10.1111/hae.13198. Epub 2017 Mar 27.
Treatment for boys with haemophilia in China is rapidly improving; however, comprehensive outcomes have not been examined prospectively.
The aim of this study was to evaluate the effect of short-term full-dose prophylaxis compared to on-demand treatment, on the Health-Related Quality of Life (HR-QoL) of boys with severe haemophilia A (HA) in China.
Boys with severe HA (FVIII<1%) completed 3 months of on-demand treatment and 3 months of full-dose prophylaxis (25 FVIII IU per kg 3x per week). The primary outcomes were child- and parent-reported Canadian Hemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT) scores. The number and type of bleeds and Activities Scale for Kids (ASK) scores were also recorded.
Analyses included 23 boys between 4 and 15.9 years of age. The number of bleeds decreased by 94% on prophylaxis (P < 0.0001, Wilcoxon Signed-Rank test). The mean child-reported CHO-KLAT scores for boys ≥7 years (n = 20) was 61.4 (±10.9) during on-demand treatment and 61.9 (±11.4) following short-term prophylaxis (P = 0.72, paired t-test). The mean parent-reported CHO-KLAT score during the on-demand phase was 54.4 (±10.5) with an increase of 3.8 points (±8.1; P = 0.04, paired t-test) following prophylaxis.
Child-reported CHO-KLAT scores were lower in boys with severe HA in China than reported in countries with access to full-dose prophylaxis. Boys reported higher HR-QoL scores than their parents. Small improvements in ASK scores were noted following the prophylaxis phase. These changes were only significant in the parent-reported CHO-KLAT scores. Longer term prospective clinical trials are needed in China to determine the impact of prophylaxis on HR-QoL in boys with severe HA.
中国血友病男孩的治疗正在迅速改善;然而,尚未对综合结果进行前瞻性研究。
本研究旨在评估短期全剂量预防与按需治疗相比,对中国重度甲型血友病(HA)男孩的健康相关生活质量(HR-QoL)的影响。
重度HA(FVIII<1%)男孩完成3个月的按需治疗和3个月的全剂量预防(每公斤25国际单位FVIII,每周3次)。主要结局是儿童和家长报告的加拿大血友病结局-儿童生活评估工具(CHO-KLAT)评分。还记录了出血的数量和类型以及儿童活动量表(ASK)评分。
分析纳入了23名4至15.9岁的男孩。预防期间出血次数减少了94%(P<0.0001,Wilcoxon符号秩检验)。≥7岁男孩(n=20)的儿童报告的CHO-KLAT平均评分在按需治疗期间为61.4(±10.9),短期预防后为61.9(±11.4)(P=0.72,配对t检验)。按需治疗阶段家长报告的CHO-KLAT平均评分为54.4(±10.5),预防后增加了3.8分(±8.1;P=0.04,配对t检验)。
中国重度HA男孩的儿童报告的CHO-KLAT评分低于有全剂量预防措施的国家报告的评分。男孩报告的HR-QoL评分高于他们的父母。预防阶段后ASK评分有小幅改善。这些变化仅在家长报告的CHO-KLAT评分中具有显著性。中国需要进行长期前瞻性临床试验,以确定预防对重度HA男孩HR-QoL的影响。